Long-term efficacy and safety of dapagliflozin in patients with inadequately controlled type 1 diabetes: pooled 52-week outcomes from the DEPICT-1 and -2 studies. - Phillip M; Mathieu C; Lind M; Araki E; di Bartolo P; Bergenstal R; Heller S; Hansen L; Scheerer MF; Thoren F; Arya N; Xu J; et al. (Diabetes, obesity & metabolism, 2021)